Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

Unique heightened aggregation of SARS-CoV-2 Delta variant spike pseudotyped particles

12 Apr 2022
NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

NVX-CoV2373 vaccine found to induce functional SARS-CoV-2-specific T cell responses

12 Apr 2022
Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

Scientists find critical role for Hippo signaling pathway in COVID-19 pathogenesis

11 Apr 2022
Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

Cryo-electron microscopy shows how Omicron BA.2 structure differs from BA.1 substantially

11 Apr 2022
The relationship between household type, COVID-19 and mental health

The relationship between household type, COVID-19 and mental health

11 Apr 2022
Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

Evidence of an increased risk of neurodegeneration after SARS-CoV-2 infection

11 Apr 2022
COVID-19 increases risk of bleeding, DVT, and pulmonary embolism

COVID-19 increases risk of bleeding, DVT, and pulmonary embolism

11 Apr 2022
Safety of COVID booster doses and obstetric outcomes in pregnancy

Safety of COVID booster doses and obstetric outcomes in pregnancy

11 Apr 2022
Nanocell COVID-19 vaccine elicits potent neutralizing response

Nanocell COVID-19 vaccine elicits potent neutralizing response

11 Apr 2022
Chromatin accessibility as an early marker of severe COVID-19

Chromatin accessibility as an early marker of severe COVID-19

11 Apr 2022
COVID-19 vaccines and reports of menstrual disorders

COVID-19 vaccines and reports of menstrual disorders

11 Apr 2022
Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

Study identifies a novel class of angiotensin receptor blockers that interfere with SARS-CoV-2 spike – ACE2 interaction

11 Apr 2022
Safety profile of colchicine in COVID-19 patients

Safety profile of colchicine in COVID-19 patients

11 Apr 2022
Pre-infection stress may increase the risk of long COVID and specific long COVID symptoms

Pre-infection stress may increase the risk of long COVID and specific long COVID symptoms

11 Apr 2022
Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

Prime-pull immunization of mice with novel subunit vaccine elicits mucosal immunity to prevent severe SARS CoV-2 infection

11 Apr 2022
Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

Exploring evolutionary trajectories of SARS-CoV-2 interacting proteins in bats and primates

11 Apr 2022
SARS-CoV-2 Omicron BA.2 sublineage outbreak aggravated by low population immunity in Hong Kong

SARS-CoV-2 Omicron BA.2 sublineage outbreak aggravated by low population immunity in Hong Kong

11 Apr 2022
The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

The human antibody response to the SARS-CoV-2 spike protein N-terminal domain in a group of previously infected individuals

11 Apr 2022
Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

Ultralong bovine antibody targets cryptic and conserved epitope on SARS-CoV and SARS-CoV-2

11 Apr 2022
Study explores phytochemical-based antivirals against SARS-CoV-2 infection

Study explores phytochemical-based antivirals against SARS-CoV-2 infection

11 Apr 2022

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback